Generic HIV Prevention Breakthrough: FDA Gives Tentative Nod to $40-a-Year Lenacapavir for 120 Countries

NEW DELHI — A generic version of a highly effective twice-yearly HIV prevention injection has cleared a major regulatory hurdle, after the United States Food and Drug Administration (FDA) gave tentative approval to Indian drugmaker Dr Reddy's version of lenacapavir on 2 November 2026, a step that global health agencies say could sharply accelerate access across low- and middle-income countries.

Dr Reddy's is the first of six manufacturers licensed by Gilead Sciences to receive tentative FDA approval for the drug, according to Reuters reporting on the announcement. The approval does not yet allow the generic to be sold in the United States, but it opens the door to sales in many of the 120 low- and middle-income countries covered by Gilead's licensing agreements — and, crucially, it gives procurement agencies and national regulators elsewhere a trusted assessment to rely on.

Illustration: A nurse giving a twice-yearly HIV prevention injection in a bright modern clinic. This is an illustration, not a photograph of a real event.

What Happened

On Monday, 2 November 2026, Dr Reddy's Laboratories said the FDA had tentatively approved its generic version of lenacapavir, a long-acting injection taken twice a year to prevent HIV infection. Lenacapavir, developed by Gilead Sciences, was approved earlier in 2026 for HIV prevention under the brand name Yeztugo and was nearly 100 per cent effective in large trials, Reuters reported.

Tentative approval is a specific FDA status: it means a drug meets the agency's standards for safety, efficacy and quality, but cannot yet be sold in the United States because of patent or exclusivity issues. For a generic aimed mainly at markets outside the United States, that distinction matters less than the signal it sends — the product has passed a rigorous review by one of the world's most closely watched regulators.

That signal, health officials say, could speed up the rollout in two ways. First, it allows global procurement agencies to move ahead with purchasing decisions. Second, it lets some national regulators fast-track their own approvals by relying on the FDA's assessment, rather than repeating a full review from scratch.

"There are some countries who would be able to fast-track regulatory approvals based on a reliance mechanism on the US FDA," Jessica Burry, a technical officer at Unitaid, told Reuters, adding that the approval could also help accelerate procurement.

Initial supplies of the generic twice-yearly injection are expected to reach a few low-income countries by the end of 2026, Burry said. Zambia could be one of the first countries to receive the drug, according to Unitaid. The broader rollout across eligible countries is expected in 2027, Dr Reddy's said.

Background

Lenacapavir belongs to a new generation of long-acting HIV prevention tools that aim to solve one of the oldest problems in the fight against HIV: adherence. Daily oral prevention pills work well when taken consistently, but in practice many people miss doses, stop, or never start — especially where clinics are far away, stigma is high, or daily pill-taking is hard to sustain.

A twice-yearly injection changes that equation. Two clinic visits a year, rather than 365 pills, could make prevention far more practical for people who need it most, including young women in sub-Saharan Africa, who bear a disproportionate share of new infections, and other groups at high risk.

Some doctors and activists say the treatment could help control the 44-year-long AIDS epidemic, which still infects 1.3 million people a year and which the World Health Organization estimates has killed 44 million people since it first emerged, Reuters reported.

The obstacle until now has been price and supply. The branded version, Yeztugo, costs about $28,000 per year in the United States, according to global health agencies cited by Reuters — a price far beyond the reach of public health programmes in low-income countries. Dr Reddy's generic version is expected to be priced at $40 per year, the agencies said in a joint statement, a reduction of more than 99 per cent.

Illustration: Generic medicine vials on a pharmacy counter with a world map behind them, symbolising affordable global access. This is an illustration, not a photograph of a real event.

That price gap is why the licensing model matters. Gilead licensed six generic manufacturers to produce lenacapavir for 120 low- and middle-income countries. Dr Reddy's is the first of the six to win tentative FDA approval; its progress sets a template that the other licensees may follow, potentially expanding supply and competition further.

Unitaid, a global health agency hosted by the World Health Organization, is providing technical and financial support to Dr Reddy's on the project, alongside the Clinton Health Access Initiative and the Wits Reproductive Health and HIV Institute, part of South Africa's University of the Witwatersrand. Separately, Indian drugmaker Hetero is working with the Gates Foundation on lenacapavir, Reuters reported.

Why It Matters

The significance of this approval is not the injection itself — that already exists as a branded product — but who will be able to get it, and how soon. For years, breakthrough HIV medicines have reached wealthy countries first and low-income countries years later, if at all. The lenacapavir generic programme is designed to compress that delay, and tentative FDA approval is the regulatory milestone that lets procurement and national approvals move in parallel rather than in sequence.

At $40 a year, the generic could be affordable for national health programmes and international donors at a scale the branded price never allowed. If initial supplies do reach a few low-income countries before the end of 2026, as Unitaid expects, and the broader rollout follows in 2027, lenacapavir could become one of the fastest transitions from a high-priced branded HIV medicine to a widely available generic prevention tool.

The timing also matters for epidemic control. With 1.3 million new infections a year, prevention tools that people can actually use consistently are as important as treatment. A twice-yearly injection removes the daily burden of pill-taking and the risk of running out of pills between clinic visits — two of the most common reasons prevention fails in practice.

There are limits to what this approval alone achieves. Tentative approval is not a sale in any country: each eligible country must still authorise the product, procurement agencies must place orders, and health systems must deliver injections, track recipients for their next dose six months later, and reach the people most at risk. Price, too, is an expectation from a joint agency statement, not a final market price in every country.

What Happens Next

The immediate next steps are regulatory and logistical. Countries that use reliance mechanisms may fast-track approvals based on the FDA assessment, while procurement agencies begin purchasing for early recipient countries, with Zambia named by Unitaid as a possible early recipient.

Watch for announcements from the other five Gilead licensees: further tentative approvals would confirm that generic supply is scaling, not depending on a single manufacturer. Watch, too, for the first confirmed deliveries before the end of 2026 — whether they arrive on schedule will be an early test of the rollout plan.

Into 2027, the broader rollout will show whether $40-a-year pricing holds at scale and whether health systems can deliver a twice-yearly injection programme to millions of people. If they can, lenacapavir generics could mark a turning point in HIV prevention: a near-perfectly effective tool, finally priced for the countries where it is needed most.

Illustration: Community health workers and residents outside a rural health centre at sunrise, symbolising wider access to HIV prevention. This is an illustration, not a photograph of a real event.

Sponsored: explore today's featured sponsored offers

FAQ

What is lenacapavir?

Lenacapavir is a long-acting HIV prevention medicine given as an injection twice a year. Developed by Gilead Sciences and sold under the brand name Yeztugo, it was nearly 100 per cent effective in large trials, according to Reuters.

What does tentative FDA approval mean?

It means the drug meets the FDA's safety, efficacy and quality standards but cannot yet be sold in the United States because of patent or exclusivity issues. It still allows procurement agencies and some national regulators to rely on the FDA assessment for their own decisions.

How much will the generic cost?

Dr Reddy's generic version is expected to be priced at $40 per year, according to a joint statement from global health agencies cited by Reuters, compared with about $28,000 per year for branded Yeztugo in the United States.

Which countries will get it first?

Initial supplies are expected to reach a few low-income countries by the end of 2026, Unitaid said, with Zambia possibly among the first recipients. The broader rollout across the 120 licensed low- and middle-income countries is expected in 2027.

Does this mean HIV prevention is now solved?

No. The approval is a major step, but countries must still authorise the product, procurement must be funded, and health systems must deliver injections and follow up recipients every six months. Prevention also still requires testing, counselling and reaching people most at risk.

Sources

• Reuters, "Dr Reddy's gets tentative US FDA nod for generic HIV prevention," 2 November 2026.
• Unitaid, Clinton Health Access Initiative and Wits Reproductive Health and HIV Institute, joint agency statement on generic lenacapavir pricing, as reported by Reuters, 2 November 2026.
• Gilead Sciences lenacapavir licensing programme (six generic licensees, 120 low- and middle-income countries), as reported by Reuters, 2 November 2026.